Pharmacokinetics of lincomycin and the evaluation of the bioequivalence of 'Lincomycin 11%' and 'Lincocin 40%' after oral administration in weaners [Polish]

摘要

In order to demonstrate the bioequivalence of an examined preparation in accordance with UE standards, in the case of the majority of farmacokinetic veterinary drugs investigations must be conducted with a reference drug on target animals. To approve the bioequivalence of the evaluated specimens it is necessary to compare values of two pharmacokinetic parameters: the area under the concentration-time (AUC) and maximal concentration (C-max). The evaluation of the bioequivalence based on the comparison of a mutual proportion of corresponding pairs of parameters (AUC, C-max, t(max)) confirmed that the examined lincomycin preparations were bioequivalent and that they can be replaced according to the required standard procedures as they have similar pharmacokinetic properties.